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Abstract
Background: Cancer antigen CA15-3 antigen is known
as a valuable marker for the management of breast
cancer.
Methods: The analytical and clinical performance
of the Access BR Monitor Immunoassay System
(Beckman Coulter) was evaluated at five different Eur-
opean sites and compared with a reference system,
defined as CA15-3 on the Elecsys System (Roche
Diagnostics).
Results: Total imprecision (%CV) of the BR Monitor
ranged between 5.5% and 11.7%, and inter-laboratory
reproducibility between 3.4% and 5.1%. Linearity
upon dilution showed a mean recovery of 98.5%
(SD"9.1%). Endogenous interferents had no influ-
ence on BR Monitor levels (mean recoveries: hemo-
globin 112%, bilirubin 111%, triglycerides 108%).
There was no high-dose hook effect up to 13,540
kU/L. Clinical performance investigated in sera from
1811 individuals showed a general correlation
between the Access BR Monitor and Elecsys CA15-3
(Rs0.797), with a slope of 1.383. CA15-3 serum levels,
as measured by the BR Monitor, were low in healthy
individuals (ns267, medians11.9 kU/L, 95th per-
centiles23.5 kU/L), higher in individuals with various
benign diseases (ns549, medianss11.3–15.6 kU/L,
95th percentiless21.6–54.6 kU/L) and even higher in
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individuals suffering from various cancers (ns995,
medianss11.2–22.8 kU/L, 95th percentiless
30.0–429.7 kU/L). Best diagnostic accuracy for cancer
detection against the relevant benign control group
by the BR Monitor was found for locoregional and
metastatic breast cancer, as well as for ovarian cancer
warea under the curve (AUC) 0.619, 0.897 and 0.774x.
Results for the reference CA15-3 assay were compar-
able (AUC 0.611, 0.887 and 0.818).
Conclusions: The Access BR Monitor provides accu-
rate methodological characteristics and demonstrates
an analytical and clinical correlation with Elecsys
CA15-3. Best diagnostic accuracy for the BR Monitor
was found in breast and ovarian cancer. Our results
also suggest a clinical value of the BR Monitor in
other cancers.
Clin Chem Lab Med 2008;46:612–22.
Keywords: breast cancer; CA15-3; diagnosis; method
comparison.
Introduction
Among all cancers, breast cancer has the highest inci-
dence rates in women in the Western industrialized
world. With more than 200,000 cases annually, it
accounts for 31% of the newly diagnosed cancers
among females in the United States (1). In many
European countries, breast cancer still ranks as the
leading cause of death among neoplastic diseases.
Because breast cancer is curable in the early stages,
great efforts have been made during recent years to
detect the malignant disease earlier and to treat it
more effectively by adjuvant and neoadjuvant thera-
pies (2, 3).
Besides progress in radiological diagnostics, serum
related markers have shown to provide valuable prog-
nostic information and to be useful for the manage-
ment of the disease, particularly in the follow-up care
after the primary therapy was applied. The recurrence
of disease is often mirrored in blood accurately, with
a lead time of several months prior to radiological
detectable tumor manifestations. The therapy efficacy
can be monitored effectively by the course of serum
markers, if interpreted by experts. Among breast can-
cer serum markers, CA15-3 antigen, CEA, and recent-
ly, HER2-neu, have proven high sensitivity for cancer
detection, particularly if used in serial measurements
(3–23).
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The tumor-associated antigen CA15-3 is a carbo-
hydrate antigen of 300 kDa belonging to the milk fat
globule mucin family. Assays for the determination of
CA15-3 use two monoclonal antibodies binding to
specific regions of the MUC 1 protein core (3, 4).
In the present study, a new assay for detection of
CA15-3 antigen was evaluated for its analytical and
clinical performance, and compared with an estab-
lished reference method. This Access BR Monitor
assay is applied on the UniCel DxI 800 Immunoassay
System (Beckman Coulter Eurocenter S.A., Nyon,
Switzerland) and uses Ma 552 as monoclonal tracer
antibody, which recognizes practically the same epi-
tope within the MUC1 protein core as the Centocor
DF3 antibody (Centocor Inc., Horsham, PA, USA), and
Ma 695 as monoclonal capture antibody, which
detects a carbohydrate epitope of MUC 1 similar to
the one recognized by the Centocor 115-D8 monoclo-
nal antibody. As most of the currently available
assays are based on the original Centocor antibody,
it is challenging to compare the clinical relevance of
the new assay using an alternative antibody, which in
consequence has led to the new name ‘‘Access BR
Monitor assay’’.
The present evaluation was performed as a Euro-
pean multicenter trial including five sites in various
countries.
Materials and methods
Assay procedure
Access BR Monitor (CA15-3 antigen) assay on the UniCel
DxI 800 Immunoassay System (Beckman Coulter) The
Access BR Monitor assay is a paramagnetic particle, two-site
immunoenzymatic (‘‘sandwich’’), chemiluminescent immu-
noassay for the quantitative determination of CA15-3 antigen
levels in human serum and plasma using the Access Immu-
noassay Systems. A sample is added to a reaction vessel
along with paramagnetic particles coated with polyclonal
goat anti-biotin antibody, mouse monoclonal-biotin conju-
gate and a buffered protein solution. After incubation in a
reaction vessel, separation in a magnetic field and washing
remove materials not bound to the solid phase. A monoclo-
nal-alkaline phosphatase conjugate is then added. After incu-
bation in a reaction vessel, materials bound to the solid
phase are held in a magnetic field, while unbound materials
are washed away. Then, the chemiluminescent substrate
Lumi-Phos 530 is added to the vessel and light generated by
the reaction is measured with a luminometer. The light pro-
duction is directly proportional to the concentration of CA15-
3 antigen in the sample. The amount of analyte in the sample
is determined from a stored, multi-point calibration curve.
Samples can be accurately measured within the analytic
range of the lower limit of detection and the highest calibra-
tor value (approximately 1.0–1000 kU/L).
For calibration, Access BR Monitor Calibrators (Cat. No.
387647: S0–S5, 2.5 mL/vial) were used. The Access BR Mon-
itor Calibrators are provided at six levels – zero and approx-
imately 10, 50, 100, 500 and 1000 kU/L. Controls, Bio-Rad
Lyphochek Tumor Marker Control (Cat. No. 580 Bilevel,
6=2 mL; Bio-Rad Laboratories, Munich, Germany), were run
in duplicates every day of the study.
CA15-3 II assay on Elecsys 2010 Immunology System (Roche
Diagnostics) The CA15-3 II assay is an electrochemolumi-
nescence immunoassay for the quantitative determination of
CA15-3 antigen levels in human serum and plasma using the
Elecsys 2010/1010 and Modular Analytics E170 Immunology
Systems (Roche Diagnostics GmbH, Penzberg, Germany).
The assay is based on a sandwich principle with the mono-
clonal antibodies 115-D8 and DF3. After predilution of 20 mL
of the sample, the antigen, a biotinylated monoclonal CA15-
3-specific antibody, and the monoclonal CA15-3 antibody
labeled with a ruthenium complex form a sandwich com-
plex. After addition of streptavidin-coated microparticles, the
complex becomes bound to the solid phase via interaction
of biotin and streptavidin. The reaction mixture is aspirated
into the measuring cell, where the microparticles are mag-
netically captured onto the surface of the electrode.
Unbound substances are then removed with ProCell buffer.
Application of a voltage to the electrode then induces chem-
iluminescent emission that is measured by a photomultiplier
tube. Results are determined via a calibration curve which is
instrument-specifically generated by two-point calibration
and a master curve provided by the manufacturer via the
reagent pack barcode.
Samples can be accurately measured within the analytic
range of 1.0–300 kU/L.
For calibration, Elecsys CA15-3 II CalSet (Cat. No.
03045846, for 4=1 mL) was used. Controls, Elecsys Preci-
Control Tumor Markers 1 and 2 (Cat No. 11776452, 2=3 mL),
were run in duplicates every day of the study.
Analytical evaluation
The analytical performance of the Access BR Monitor assay
was evaluated by all five centers in parallel, in particular
imprecision, inter-laboratory reproducibility, minimum
detectable concentration and linearity upon dilution. The
influence of endogenous interferents and high-dose hook
effect was tested in the laboratories of Munich, Barcelona
and Aachen; interferences of sample type and sample
storage were only tested in Munich.
Imprecision Two controls (Bio-Rad) and three human
serum pools prepared by each center, including a low, medi-
um and high concentration pool were tested in triplicate,
with two runs per day for at least 10 days according to the
guidelines of the CLSI (Clinical and Laboratory Standards
Institute, formerly NCCLS; document NCCLS-EP5-A). Data
analysis included calculation of within-run and total impre-
cision and was performed by Acomed Statistics, Leipzig,
Germany.
Inter-laboratory reproducibility Inter-laboratory reproduci-
bility was evaluated using the two controls across the five
evaluation sites.
Minimum detectable concentration The minimum detect-
able concentration was defined as the BR Monitor concen-
tration corresponding to a signal two standard deviations
above the main value of 10 replicates of the S0 calibrator
tested on each of 3 days.
Linearity upon dilution A total of 22 samples, with six of
them above the assay dynamic range ()1000 kU/L) and 16
of them between 200 and 1000 kU/L, were diluted with the
appropriate Access BR Monitor diluent to obtain a minimum
of four dilutions within the assay dynamic range. Dilutions
were prepared separately in one to two steps using calibrat-
ed pipettes and were carried out in four replicates. Recov-
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eries were calculated with respect to the highest concen-
tration in the dynamic range.
Sample type interference Samples were obtained from 10
patients with unsuspicious laboratory findings, one serum in
tubes with kaolin, one lithium-heparinate plasma, one EDTA
plasma and one citrate plasma. Sample type interference
was tested in duplicates. Recoveries were calculated with
respect to the concentration in the serum sample.
Sample storage interference Samples from seven of these
patients were measured natively and after storage at 48C and
–208C for 1 day. Both storage modalities were compared
with the native measurements.
Further, serum and lithium-heparinate plasma samples of
the 10 patients were stored at –208C for 6 months and meas-
urements were compared with the original –208C data to test
the long-term stability.
Endogenous interferents The influence of bilirubin, hemo-
globin and triglycerides was tested on a human serum pool
with high CA15-3 concentration. This pool was diluted
with a serum containing high bilirubin concentration
()0.062 mmol/L), with a serum with high hemoglobin level
(ca. 0.855 mmol/L; normal serum spiked with hemolyzed
blood sample) and with a serum with high triglyceride con-
centration ()0.006 mmol/L). These test solutions were tested
with the Access BR Monitor assay and compared to the con-
trol solutions obtained from the same pool diluted in the
same way with the Sample Diluent A (Catalog Number
81908) instead of the interfering substance. Each test solu-
tion and each control solution were assayed 10 times in con-
stantly decreasing proportions. Recoveries were calculated
with respect to the concentration of the undiluted serum
pool. Additionally, 10 samples with high known rheumatoid
factor concentration were tested in duplicate.
High-dose hook effect Serial 10-fold dilutions of five differ-
ent samples with very high CA15-3 concentrations above
3000 kU/L were tested. Recoveries were calculated with
respect to the highest concentration in the dynamic range.
Clinical performance
The clinical performance of the Access BR Monitor assay
was evaluated by two sites (Munich and Barcelona). All clin-
ical samples were sent to the Institute of Clinical Chemistry
of the University Hospital Munich, to be tested using the
Access BR Monitor assay on the UniCel DxI 800 Immuno-
assay System (Beckman Coulter) and compared to the ref-
erence CA15-3 II assay on the Elecsys 2010 Immunology
System (Roche Diagnostics).
Healthy individuals The normal reference interval for the
BR Monitor was established from 267 samples, including 113
sera from men and 154 sera from non-pregnant women.
Median age was 39.4 years (range 17–81 years). The subject
inclusion/exclusion criteria were as follows:
• normal, apparently healthy subjects (evaluated clinically
and by clinical chemistry parameters),
• adults older than 18 years were tested,
• no personal history of cancer disease, renal failure or
liver disease.
Age and sex were mandatory for all samples enrolled.
Samples with hemolysis, bilirubin or lipemia were excluded.
Individuals with benign diseases BR Monitor results were
determined in a total of 549 individuals diagnosed with
benign diseases, among them 148 benign breast diseases,
109 benign gynecological diseases (ovarian cysts, endomet-
riosis, uterine leiomyoma, etc.), 155 benign gastrointestinal
diseases (ulcerous colitis, Crohn’s disease, liver cirrhosis,
hepatitis, pancreatitis, cholelithiasis, etc.), 44 benign lung
diseases (tuberculosis, sarcoidosis, pneumonia, etc.), 66
benign urological diseases (nephrolithiasis, renal failure,
etc.) and 27 other benign diseases, and compared with the
reference system.
Individuals with malignant diseases BR Monitor results
were determined in a total of 995 individuals diagnosedwith
cancer diseases and compared with the reference system.
The cancer diseases included 81 ovarian cancers, 57 other
gynecological cancers, 62 pancreatic cancers, 26 gastric
cancers, 58 hepatocellular cancers, 113 colorectal cancers, 82
lung cancers, 57 urological cancers (bladder and kidney) and
43 prostate cancers. We also studied 416 patients with breast
cancer, among them 207 with locoregional and 151 with
metastatic disease. For 58 patients, no exact staging infor-
mation about the active disease state was available.
All samples were obtained from patients with active dis-
ease, typically before surgery as first treatment modality, or
in some cases at time of recurrent disease.
Statistical analysis
The BR Monitor assay and reference method were compared
using regression equations according to Passing and Bablok.
Normalized differences from mean values were calculated
according to Bland and Altman.
In healthy individuals, the frequency distribution for the BR
Monitor and reference method was defined including 25th
percentile, median, mean, upper reference limit (URL) of a
normal population at 95th, 97.5th and 99th percentiles.
In all studied groups, distribution of BR Monitor and ref-
erence method concentrations were presented graphically,
as well as statistically (median, range, 95th percentile).
The analysis of the sensitivity/specificity for breast cancer
included receiver operating characteristic (ROC) curves,
using benign breast diseases as the control group. Similarly,
ROC curves were established for ovarian cancer vs. benign
gynecological diseases, lung cancer vs. benign lung dis-
eases, and colorectal cancer vs. benign gastrointestinal dis-
eases. Further, at 95% specificity against the respective
benign control group, the sensitivity for each cancer type
was calculated, and also the area under the curve (AUC) of
the corresponding ROC curves with the corresponding 95%
confidence interval.
Results
Analytical evaluation
Imprecision Within-run imprecision of the low con-
trol (10.3–11.7 kU/L) ranged in the various centers
between 5.2% and 8.1%, and of the high control
(27.2–29.8 kU/L) between 6.2% and 6.8%. Within-run
imprecision of the low serum pools (ranging from 8.0
to 29.8 kU/L) was between 5.3% and 6.8%, of the
medium serum pools (ranging from 17.3 to 109 kU/L)
between 5.3% and 7.7%, and of the high serum pools
(ranging from 169 to 688 kU/L) between 4.3% and
11.6%.
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Figure 1 Linearity upon dilution.
Samples with high BR Monitor levels were diluted by one to
two steps and recoveries were calculated for various dilution
steps.
Figure 2 Influence of endogenous interferences.
Samples were spiked with various concentrations of hemo-
globin (●), bilirubin () and triglycerides (m) and recoveries
of BR Monitor levels were calculated for various dilution
steps.
Total imprecision of the low control (10.3–11.7
kU/L) ranged in the various centers from 6.6% to
10.6%, and of the high control (27.2–29.8 kU/L) from
7.6% to 9.1%. Total imprecision of the low serum
pools (8.0–29.8 kU/L) was from 6.8% to 9.1%, of the
medium serum pools (17.3–109 kU/L) was from 6.8%
to 10.7%, and of the high serum pools (169–688
kU/L) from 5.5% to 11.7%.
Inter-laboratory reproducibility Inter-laboratory im-
precision of the low control (10.3–11.7 kU/L) was
found to be 5.1%, and of the high control
(27.2–29.8 kU/L) 3.4%.
Minimum detectable concentration The minimum
detectable concentration was found to be -1.0 kU/L
in all centers. All these results were in the very low
range and have no clinical relevance.
Linearity upon dilution Linearity upon dilution re-
vealed a mean recovery of all dilutions of 98.5% in all
centers, with a standard deviation of 9.1% (minimum
72.4%, maximum 145%) (Figure 1).
Sample type interference Samples from ten patients
with unsuspicious laboratory findings were tested on
sample type interference. BR Monitor measurements
in kaolin serum, lithium-heparinate plasma and EDTA
plasma were very comparable. Mean recovery in
heparinate plasma was 102%, with a standard devia-
tion of 11.4% (minimum 80.2%, maximum 120%).
Mean recovery in EDTA plasma was 97.1%, with a
standard deviation of 8.4% (minimum 83.8%, maxi-
mum 111%). BR Monitor values in citrate plasma
were lower than BR Monitor values in serum, with a
mean recovery of 84.7% and a standard deviation of
6.0% (minimum 75.0%, maximum 92.3%).
Sample storage interference Samples from seven of
these patients were measured natively, after storage
at 48C and at –208C each for 1 day. Both storage con-
ditions tested did not affect the BR Monitor recovery.
After storage at 48C, mean recovery was 103%, with
a standard deviation of 7.1% (minimum 88.0%, max-
imum 109%). After storage at –208C, mean recovery
was 102%, with a standard deviation of 10.2% (mini-
mum 89.8%, maximum 117%).
In addition, serum and lithium-heparinate plasma
samples of the 10 patients were stored at –208C for
6 months and measurements were compared with the
original –208C data to test the long-term stability.
Again, storage had no influence on marker levels.
When serum samples were stored at –208C for
6 months, mean recovery was 110%, with a standard
deviation of 7.8% (minimum 96.9%, maximum 119%).
When lithium-heparinate plasma samples were
stored at –208C for 6 months, mean recovery was
110%, with a standard deviation of 7.6% (minimum
93.9%, maximum 120%).
Endogenous interferents The potentially confound-
ing impact of endogenous interferents, such as hemo-
globin, bilirubin and triglycerides, was tested at two
centers. Stepwise dilution of a serum pool having
high CA15-3 level with a serum sample with high
concentration of the relevant interferent and, alter-
natively, with sample diluent which was free of any
contamination showed that neither interferent had
any influence on BR Monitor level.
Dilution with hemoglobin-spiked serum resulted in
a mean recovery of 113%, with a standard deviation
of 19.7% (minimum 87.7%, maximum 161%). There
was no trend of continuously changing BR Monitor
values when increasing amounts of hemoglobin were
added (Figure 2).
In the dilution series with bilirubin-rich serum, one
random outlier was identified (recovery of 209%).
When this value was excluded, mean recovery was
106%, with a standard deviation of 12.3% (minimum
91.3%, maximum 137%). Despite the outlier, there
was no trend of continuously changing BR Monitor
values when increasing amounts of bilirubin were
added (Figure 2).
Dilution with triglyceride-rich serum yielded a mean
recovery of 108%, with a standard deviation of 14.8%
(minimum 88.7%, maximum 153%). There was no
trend of continuously changing BR Monitor values
when increasing amounts of triglycerides were added
(Figure 2).
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:40
616 Molina et al.: Analytical and clinical evaluation of BR Monitor assay
Article in press - uncorrected proof
Figure 3 Influence of high dose hook effect.
Samples with extremely high BR Monitor levels )3000
kU/L were diluted by 1:10 steps.
Rheumatoid factor A total of 14 serum samples with
high rheumatoid factor concentrations (mean
209.4 kU/L, standard deviation 298.0 kU/L, minimum
26.7 kU/L, maximum 1131 kU/L) were tested for the
potential confounding effect of rheumatoid factor on
BR Monitor values. However, all BR Monitor levels
were very low in the range of healthy individuals.
Mean value was 17.6 kU/L, with a standard deviation
of 8.6 kU/L (minimum 7.1 kU/L, maximum 42.3 kU/L).
High-dose hook effect In total, five serum samples
with very high CA15-3 levels (3558–13,540 kU/L) were
tested in dilution series on a potential high-dose hook
effect. As illustrated graphically in Figure 3, all sam-
ples demonstrated a linear dilution response. Mean
recovery in the curves was 101%, with a standard
deviation of 13.6% (minimum 80.8%, maximum
136%) (Figure 3).
Clinical performance
Method comparison Comparison of the Access BR
Monitor assay and the Elecsys CA15-3 assay
(ns1811) yielded a correlation coefficient of Rs0.797,
with a slope of 1.383 and an intercept of –0.011.
A large number of samples (1768 out of 1811) were
found to have values up to 200 kU/L. For this group,
a correlation of Rs0.807, with a slope of 1.353 and an
intercept of q0.302, was found. Values up to 50
kU/L were found in 1619 out of 1811 samples. For this
clinically relevant group, the coefficient of correlation
was Rs0.780, with a slope of 1.294 and an intercept
of q0.883 (Figure 4).
Healthy individuals For the Access BR Monitor, the
95th percentile URL of a healthy population (ns267)
was determined to be 23.5 kU/L. The value distribu-
tion ranged from 2.3 to 36.8 kU/L. Mean was at
12.8 kU/L and the median was at 11.9 kU/L. The 25th
percentile was calculated as 8.7 kU/L, 97.5th percen-
tile at 28.1 kU/L and 99th percentile at 30.1 kU/L.
Females had slightly higher levels (median at 12.8
kU/L, 95th percentile at 25.0 kU/L) than males (median
at 11.1 kU/L, 95th percentile at 20.6 kU/L). The meth-
ods correlated reasonably well with each other
(Rs0.757); however, a slope of 1.357 with lower val-
ues for the BR Monitor compared with the CA15-3
Elecsys was calculated (Figure 5, Table 1).
Individuals with benign diseases Of 549 individuals
diagnosed with benign diseases, patients with benign
breast and gynecological diseases demonstrated the
lowest levels for the Access BR Monitor and were in
the range of healthy individuals (medians at 11.3 and
12.0 kU/L, 95th percentiles at 22.3 and 21.6 kU/L).
Slightly higher levels were found in benign gastro-
intestinal, lung and urological diseases (medians at
13.7, 15.2 and 12.7 kU/L; 95th percentiles at 32.3, 32.1
and 54.6 kU/L). Particularly, renal insufficiency could
cause moderate BR Monitor elevations. In all benign
diseases, both methods yielded a generally accept-
able correlation (Rs0.739) and a notable slope of
1.236. Details of distribution of values are listed in
Table 1 and Figure 5.
Individuals with malignant diseases Of 995 individ-
uals diagnosed with malignant diseases, patients with
breast cancer yielded the highest levels for the Access
BR Monitor, with values exceeding 3000 kU/L. The
median value in locoregional breast cancer was cal-
culated at 13.7 kU/L and 95th percentile at 42.3 kU/L,
while in metastatic breast cancer the median was
found to be 48.4 kU/L and 95th percentile at 993.8
kU/L. However, high levels were observed in patients
with ovarian cancer (median at 22.8 kU/L, 95th per-
centile at 164.7 kU/L) and with lung cancer (median at
21.0 kU/L, 95th percentile at 161.3 kU/L). In contrast,
strongly elevated BR Monitor values were only found
rarely in individuals with gastrointestinal cancers,
such as colorectal cancer (95th percentile at 33.4
kU/L) and gastric cancer (95th percentile at 31.3
kU/L), as well as in urological cancers, such as blad-
der cancer (95th percentile at 30.0 kU/L) and prostate
cancer (95th percentile at 33.8 kU/L). Also in this sub-
group, both methods correlated with each other
(Rs0.801) and a slope of 1.389 was found. Details of
distribution of values are listed in Table 1 and Figure
6.
Sensitivity for cancer disease In addition to the com-
parison of the absolute concentrations of both meth-
ods in various patient groups with benign and
malignant diseases, the diagnostic capacity of the
Access BR Monitor (CA15-3 antigen) assay on the
UniCel DxI 800 Immunoassay System was tested by
ROC curves showing the profile of sensitivity and
specificity over the whole range of values and was
compared to that of the CA15-3 assay on the Elecsys
2010 Immunology System. According to the guide-
lines of the European Group on Tumor Markers
wEGTM (3)x, all cancer types were compared with the
respective benign disorders as the relevant control
group.
Concerning their diagnostic capacity, both methods
showed very comparable results for all cancer types
investigated – despite the general slope in the con-
centrations. This good diagnostic correlation was
expressed by similar values for AUC with overlapping
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Figure 4 Method comparison of the BR Monitor with the reference method.
Correlation of Access BR Monitor (Beckman Coulter) and Elecsys CA15-3 (Roche Diagnostics) concentrations were calculated
(A) for the range -200 kU/L and (B) for the range -50 kU/L. (C) Normalized differences from mean values were calculated
according to Bland and Altman.
Figure 5 Value distribution of the BR Monitor and reference method in controls.
Dot plot of the (●) Access BR Monitor (Beckman Coulter) and (e) Elecsys CA15-3 (Roche Diagnostics) concentrations in serum
samples of healthy individuals and individuals with various benign diseases.
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Table 1 BR Monitor concentrations in sera of cancer patients and controls.
Diagnosis n Method Median, Range, 95th percentile,
kU/L kU/L U/L
Healthy individuals 267 Dxl 800 11.9 2.3–36.8 23.5
Elecsys 15.1 3.0–42.9 31.5
Benign breast diseases 148 Dxl 800 11.3 3.9–39.3 22.3
Elecsys 17.1 4.9–41.4 31.1
Benign gynecological diseases 109 Dxl 800 12.0 3.5–28.3 21.6
Elecsys 14.2 2.0–35.0 27.5
Benign gastrointestinal diseases 155 Dxl 800 13.7 1.0–49.4 32.3
Elecsys 18.0 4.1–59.4 36.3
Benign lung diseases 44 Dxl 800 15.2 6.5–35.4 32.1
Elecsys 18.0 9.0–45.1 41.0
Benign urological diseases 66 Dxl 800 12.7 3.6–129.0 54.6
Elecsys 17.0 4.9–68.8 39.2
Other benign diseases 27 Dxl 800 15.6 6.6–63.5 51.0
Elecsys 17.1 8.0–81.1 61.1
Breast cancer 416 Dxl 800 16.9 4.2–3335 429.7
Elecsys 23.0 6.0–3890 450.2
Breast cancer (locoregional) 207 Dxl 800 13.7 4.2–475.0 42.3
Elecsys 18.9 6.4–1035 53.4
Breast cancer (metastatic) 151 Dxl 800 48.4 5.7–3335 993.8
Elecsys 66.0 6.0–3890 1585.6
Ovarian cancer 81 Dxl 800 22.8 2.8–324.3 164.7
Elecsys 35.5 5.5–419.0 262.5
Gynecological cancer 57 Dxl 800 16.6 4.1–94.3 60.2
Elecsys 24.5 5.8–285.0 136.4
Gastric cancer 26 Dxl 800 11.2 2.2–35.9 31.3
Elecsys 18.1 2.6–108.0 84.4
Hepatocellular cancer 58 Dxl 800 17.1 6.5–466.6 87.0
Elecsys 21.8 7.3–2258 122.5
Pancreatic cancer 62 Dxl 800 14.3 2.4–388.0 56.1
Elecsys 21.7 4.7–535.0 62.0
Colorectal cancer 113 Dxl 800 13.8 5.1–114.9 33.4
Elecsys 20.3 7.1–118.0 48.9
Lung cancer 82 Dxl 800 21.0 5.0–1729.0 161.3
Elecsys 23.6 7.0–241.0 134.0
Urological cancer 57 Dxl 800 14.0 5.5–51.0 30.0
Elecsys 20.5 7.7–52.1 34.1
Prostate cancer 43 Dxl 800 15.3 4.2–38.6 33.8
Elecsys 20.5 7.7–50.7 43.3
Median, range and 95th percentile limit of the Access BR Monitor (Beckman Coulter) for healthy individuals, patients with
benign and malignant diseases. Comparison with Elecsys CA15-3 (Roche Diagnostics) concentrations.
Figure 6 Value distribution of the BR Monitor and reference method in cancer patients.
Dot plot of the (●) Access BR Monitor (Beckman Coulter) and (e) Elecsys CA15-3 (Roche Diagnostics) concentrations in serum
samples of individuals with various malignant diseases.
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Table 2 Diagnostic capacity of BR Monitor for various cancer diseases.
Diagnosis n Method Sensitivity at 95% AUC Confidence
specificity vs. respective interval
benign diseases
Breast cancer 416 Dxl 800 38.7 0.708 0.665–0.750
Elecsys 35.6 0.696 0.652–0.740
Breast cancer (locoregional) 207 Dxl 800 18.8 0.619 0.561–0.677
Elecsys 16.4 0.611 0.553–0.669
Breast cancer (metastatic) 151 Dxl 800 76.2 0.897 0.859–0.935
Elecsys 73.5 0.887 0.847–0.926
Ovarian cancer 81 Dxl 800 53.1 0.774 0.701–0.848
Elecsys 60.5 0.812 0.746–0.879
Gynecological cancer 57 Dxl 800 36.8 0.694 0.604–0.784
Elecsys 38.6 0.755 0.674–0.835
Gastric cancer 26 Dxl 800 3.8 0.386 0.262–0.511
Elecsys 15.4 0.469 0.333–0.605
Hepatocellular cancer 58 Dxl 800 17.2 0.635 0.549–0.720
Elecsys 13.8 0.647 0.564–0.730
Pancreatic cancer 62 Dxl 800 6.5 0.523 0.432–0.614
Elecsys 11.3 0.584 0.494–0.674
Colorectal cancer 113 Dxl 800 7.1 0.519 0.449–0.589
Elecsys 10.6 0.557 0.486–0.627
Lung cancer 82 Dxl 800 32.9 0.631 0.536–0.726
Elecsys 26.8 0.641 0.546–0.735
Renal cancer 29 Dxl 800 0.0 0.563 0.444–0.682
Elecsys 10.7 0.646 0.525–0.767
Bladder cancer 28 Dxl 800 3.4 0.528 0.407–0.650
Elecsys 10.3 0.554 0.430–0.679
Survey on the diagnostic capacity of the Access BR Monitor (Beckman Coulter) for various cancer diseases when compared
with their respective benign diseases as control groups and comparison with the Elecsys CA15-3 (Roche Diagnostics). Area
under the curve (AUC) of the receiver operating characteristic curves and sensitivity at 95% specificity vs. the respective
benign diseases indicate the discriminating power.
confidence intervals, as well as by the sensitivity for
cancer detection at 95% specificity of benign diseases
(Table 2). Among all cancers, breast cancer and ovar-
ian cancer showed the highest AUC values for both
methods when compared with benign breast and
gynecological diseases, respectively, particularly in
metastatic disease.
For patients with locoregional breast cancer, the
AUC was 0.619 for the Access BR Monitor and 0.611
for the Elecsys CA15-3. The respective sensitivity at
95% specificity vs. benign breast diseases was 18.8%
for the Access BR Monitor and 16.4% for the Elecsys
CA15-3. For patients with metastatic breast cancer,
the AUC was significantly higher at 0.897 for the
Access BR Monitor and 0.887 for the Elecsys CA15-3.
The respective sensitivity at 95% specificity vs. benign
breast diseases was calculated at 76.2% for the
Access BR Monitor and 73.5% for the Elecsys CA15-3
(Figure 7, Table 2). In ovarian cancer, the AUC was
0.774 for the Access BR Monitor and 0.812 for the
Elecsys CA15-3, with a sensitivity of 53.1% (Access BR
Monitor) and 60.5% (Elecsys CA15-3) at 95% specific-
ity vs. benign gynecological diseases. In addition, the
Access BR Monitor and Elecsys CA15-3, respectively,
showed diagnostic power for other cancers, such as
lung cancer and other gynecological cancers, too (Fig-
ure 8, Table 2).
Discussion
Several studies have shown that CA15-3 is the marker
of first choice for the management of breast cancer.
If no renal insufficiency is present, which can also pro-
voke elevated CA15-3 levels, high preoperative and
pretherapeutic CA15-3 concentrations are helpful in
suggesting differential diagnosis of symptomatic
breast cancer. Moreover, prognostic relevance of
pretherapeutic CA15-3-levels for overall survival of
breast cancer patients undergoing surgery and/or
receiving systemic chemo- and/or radiotherapy was
found repeatedly by several groups. Similarly, the
usefulness of CA15-3 for therapy monitoring, as well
as early detection of diseases progression in breast
cancer patients, is widely recognized and accepted. In
addition to breast cancer, CA15-3 is detected in ovar-
ian, endometrial, cervical, lung and gastrointestinal
cancer tissues, as well as in the serum of these
patients (3–23).
In the present study, the new Access BR Monitor
assay, which uses the monoclonal antibodies Ma 552
and Ma 695 for detection of the CA15-3 antigen, was
tested for analytical and clinical performance. The
guidelines of the EGTM (3) require a new diagnostic
method to be investigated for potential influence of
organ-specific and non-specific influences which
might alter the metabolism of the antigen. Further,
the new method has to be compared with a current
accepted method to demonstrate its superiority, or at
least equivalence, for the intended indication.
First, we therefore performed a thorough analytical
evaluation at five European centers, to test the basic
preconditions for routine application. Then, a large
panel of sera from 1811 individuals was investigated.
These individuals included healthy individuals,
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Figure 7 Diagnostic capacity of the BR Monitor and reference method for detection of metastatic and locoregional breast
cancer.
Profiles of sensitivity and specificity over the whole range of cut-off values are shown by receiver operating characteristic
(ROC) curves for (A) metastatic breast cancer (ns151) and (B) locoregional breast cancer (ns207) vs. benign breast diseases
(ns148). (●) Access BR Monitor (Beckman Coulter) and (e) Elecsys CA15-3 (Roche Diagnostics).
Figure 8 Diagnostic capacity of the BR Monitor and reference method for detection of ovarian cancer, lung cancer and
colorectal cancer.
Profiles of sensitivity and specificity over the whole range of cut-off values are shown by receiver operating characteristic
(ROC) curves for (A) ovarian cancer (ns81) vs. benign gynecological diseases (ns109), (B) lung cancer (ns82) vs. benign
lung diseases (ns44) and (C) colorectal cancer (ns113) vs. benign gastrointestinal diseases (ns155). (●) Access BR Monitor
(Beckman Coulter) and (e) Elecsys CA15-3 (Roche Diagnostics).
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patients with gastrointestinal and other benign dis-
eases and many patients with various cancer diseases
that might be relevant for differential diagnosis by
CA15-3. The entire clinical evaluation of the Access
BR Monitor was carried out in parallel with the Elec-
sys CA15-3, a current standard method, using the
same sera from the same patients, to enable a fair
comparison of both methods.
The analytical performance for the BR Monitor
assay was accurate with a low, however, not yet opti-
mal within-run, total and inter-laboratory imprecision.
Additionally, we observed suitable recoveries during
linearity upon dilution testing and no high-dose hook
effect up to 13,540 kU/L. Sample type interference
studies demonstrated that serum, lithium-heparinate
plasma and EDTA plasma can be used interchange-
ably. However, BR Monitor levels in citrate plasma
were approximately 15% lower than in serum. Con-
cerning sample storage, it is important to note that
freezing did not affect the marker values, and long-
term storage for 6 months at –208C still yielded stable
results. Of clinical relevance is the finding that endo-
genous interferents, such as hemoglobin, bilirubin,
triglycerides and rheumatoid factor, do not influence
BR Monitor concentrations.
Comparison of the Access BR Monitor with Elecsys
CA15-3 showed a reasonably good correlation for all
patients and for the various subgroups investigated.
However, a notable slope with 20%–40% lower con-
centrations for the BR Monitor was observed. Similar
results have been described earlier by several authors
who performed method comparisons of CA15-3
assays (11, 12). This fact shows the necessity to inter-
pret the absolute results with care, to maintain the
same method in serial investigations and to double
the values when CA15-3 methods are changed.
In our study, healthy individuals had very low val-
ues, as measured with both methods. URLs were only
slightly different and were in the range of the values
indicated by both manufacturers (Beckman Coulter
23.5 kU/L, Roche Diagnostics 31.5 kU/L).
Levels in sera of individuals diagnosed with benign
breast and gynecological diseases were similar to
those of healthy individuals. Patients with benign
lung, gastrointestinal and urological diseases had
slightly higher BR Monitor levels. Particularly, renal
insufficiency is known to potentially cause elevated
levels (24, 25). In this group, single values reached
more than 100 kU/L.
CA15-3 concentrations in patients suffering from
various cancers were also elevated. However, in
some cancer types, medians and 95th percentiles
were comparable with those of benign diseases, e.g.,
for bladder, renal, prostate, colorectal and gastric can-
cer. In contrast, ovarian, lung, hepatocellular and
other gynecological cancers demonstrated more
pronounced CA15-3 elevations, which reached
)1000 kU/L in some patients.
The best diagnostic accuracy of the BR Monitor for
cancer detection against the relevant benign control
group was found for breast cancer and for ovarian
cancer. Particularly in metastatic breast cancer, a high
sensitivity of 76.2% for cancer detection at 95% spec-
ificity vs. benign breast diseases was found, while it
was only 18.8% in locoregional disease. These nota-
ble differential diagnostic results underline the high
relevance of CA15-3 antigen for the management of
breast cancer and its impact in follow-up investiga-
tions – also for those patients who had not shown an
initial release during locoregional disease. Important-
ly, BR Monitor results also correspond very well with
the diagnostic accuracy of the CA15-3 reference meth-
od for cancer detection demonstrated by the similar
AUC values and the broadly overlapping confidence
intervals. Though the diagnostic power of the BR
Monitor is somewhat lower for other tumor types, it
has to be pointed out that for lung and gynecological
cancer the AUC was still higher than 0.6 and the sen-
sitivity at 95% specificity vs. the relevant benign con-
trol group higher than 20% – once again, both
methods were very comparable. This diagnostic per-
formance in cancer types for which CA15-3 was not
considered as a relevant marker suggests there may
be value in including CA15-3 with other diagnostically
relevant markers in future multiparametric analyses.
In combination with well known markers, e.g., CA125
in ovarian cancer, as well as with CYFRA 21-1, carcino-
embryonic antigen, neuron-specific enolase and pro-
gastrin-releasing peptide in lung cancer, CA15-3 and
other mucin markers might be helpful to further
improve the diagnostic accuracy (26, 27).
Conclusions
The Access BR Monitor is a new assay based on an
alternative antibody for CA15-3 antigen detection. The
Access BR Monitor provides accurate methodological
characteristics for use in routine laboratory and dem-
onstrates an acceptable analytical and clinical corre-
lation with the Elecsys CA15-3. The BR Monitor shows
a high diagnostic accuracy in breast cancer and it is
a valuable marker in the management of this disease.
Our results also suggest a clinical value of the BR
Monitor in gynecological (ovarian and endometrial)
and lung cancers. If the CA15-3 antigen method is
changed, parallel measurements of CA15-3 with both
methods for an appropriate time span are strongly
recommended.
Acknowledgements
We appreciate the excellent statistical support of Thomas
Keller from Acomed Statistics, Leipzig, Germany.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C,
et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:
106–30.
2. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J,
Curran WJ, et al. Clinical cancer advances 2006: major
research advances in cancer treatment, prevention, and
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:40
622 Molina et al.: Analytical and clinical evaluation of BR Monitor assay
Article in press - uncorrected proof
screening – a report from the American Society of
Clinical Oncology. J Clin Oncol 2007;25:146–62.
3. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R,
Gion M, et al. Tumor markers in breast cancer – Euro-
pean Group on Tumor Markers recommendations.
Tumour Biol 2005;26:281–93.
4. Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW.
Use of a murine monoclonal antibody for detection of
circulating plasma DF3 antigen levels in breast cancer
patients. J Clin Invest 1985;75:1671–8.
5. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M,
et al. Use of serial carcinoembryonic antigen and CA
15.3 assays in detecting relapses in breast cancer
patients. Breast Cancer Res Treat 1995;36:41–8.
6. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M,
et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients
with breast cancer: prognostic value. Breast Cancer Res
Treat 1998;51:109–19.
7. Molina R, Jo J, Filella X, Zanon G, Farrus B, Munoz M,
et al. C-erbB-2, CEA and CA 15.3 serum levels in the early
diagnosis of recurrence of breast cancer patients. Anti-
cancer Res 1999;19:2551–5.
8. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz
M, et al. Prospective evaluation of CEA and CA 15.3 in
patients with locoregional breast cancer. Anticancer Res
2003;23:1035–41.
9. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz
M, et al. Prospective evaluation of tumor markers (c-
erbB-2 oncoprotein, CEA and CA 15.3) in patients with
locoregional breast cancer. Anticancer Res 2003;23:
1043–50.
10. Stieber P, Nagel D, Ritzke C, Rossler N, Kirsch CM, Eier-
mann W, et al. Significance of bone alkaline phospha-
tase, CA15-3 and CEA in the detection of bone
metastases during the follow-up of patients suffering
from breast carcinoma. Eur J Clin Chem Clin Biochem
1992;30:809–14.
11. Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R,
Bonfrer JM, et al. Evaluation of the analytical and clinical
performance of the Elecsys CA15-3 immunoassay. Clin
Chem 2001;47:2162–4.
12. Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R,
Bonfrer JM, et al. Clinical evaluation of the Elecsys
CA15-3 test in breast cancer patients. Clin Lab 2003;49:
15–24.
13. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE,
Schmitt UM, et al. Serum CEA and CA15-3 as prognostic
factors in primary breast cancer. Br J Cancer 2002;86:
1217–22.
14. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S,
Bauerfeind I, Stieber P. Importance of CEA and CA15-3
during disease progression in metastatic breast cancer
patients. Anticancer Res 2007;27:1963–8.
15. Gion M, Cappelli G, Mione R, Vignati G, Fortunato A,
Saracchini S, et al. Variability of tumor markers in the
follow-up of patients radically resected for breast cancer.
Tumour Biol 1993;14:325–33.
16. Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vigna-
ti G, et al. Evaluation of critical differences of CEA and
CA 15.3 levels in serial samples from patients operated
for breast cancer. Int J Biol Markers 1994;9:135–9.
17. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L,
Mione R, et al. Prognostic role of serum CA15.3 in 362
node-negative breast cancers. An old player for a new
game. Eur J Cancer 2002;38:1181–8.
18. Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R,
Namer M, et al. The prognostic significance of increasing
marker levels in metastatic breast cancer patients with
clinically complete remission, partial remission or stable
disease. Int J Biol Markers 1998;13:10–5.
19. Al-azawi D, Kelly G, Myers E, McDermott EW, Hill AD,
Duffy MJ, et al. CA15-3 is predictive of response and dis-
ease recurrence following treatment in locally advanced
breast cancer. BMC Cancer 2006;6:220.
20. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E,
Crown J, et al. High preoperative CA15-3 concentrations
predict adverse outcome in node-negative and node-
positive breast cancer: study of 600 patients with histo-
logically confirmed breast cancer. Clin Chem 2004;50:
559–63.
21. Duffy MJ. Serum tumor markers in breast cancer: are
they of clinical value? Clin Chem 2006;52:345–51.
22. Shering SG, Sherry F, McDermott EW, O’Higgins NJ,
Duffy MJ. Preoperative CA15-3 concentrations predict
outcome of patients with breast carcinoma. Cancer 1998;
83:2521–7.
23. Coveney EC, Geraghty JG, Sherry F, McDermott EW,
Fennelly JJ, O’Higgins NJ, et al. The clinical value of CEA
and CA15-3 in breast cancer management. Int J Biol
Markers 1995;10:35–41.
24. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, et
al. Tumor markers in patients with chronic renal failure.
Int J Biol Markers 1990;5:85–8.
25. Cases A, Filella X, Molina R, Ballesta AM, Lo´pez-Revert
J, Revert L. Tumor markers in chronic renal failure and
hemodialysis patients. Nephron 1991;57:183–6.
26. Molina R, Filella X, Auge´ JM, Fuentes R, Bover I, Rifa J,
et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC
and NSE) in NSCLC patients as an aid in histological
diagnosis and prognosis: comparison with the main
clinical and pathological prognostic factors. Tumor Biol
2003;24:209–18.
27. Molina R, Auge JM, Marradas R, Vin˜olas N, Escudero
JM, Filella X. Mucins (CA 125, CA 19.9, CA 15.3 and
TAG-72) as tumor markers in patients with lung cancer:
comparison with CYFRA 21-1, CEA, SCC and NSE. Eur J
Cancer 2007. In press.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:40
